Emerging Therapies in Metabolic Health: A Comprehensive Review of GLP‐1, GIP, and Glucagon Agonists
Journal of Peptide Science · 2026
DOI: 10.1002/psc.70083 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Peptide Science, 2026. Verfasst von Mohammed Shareef Khan und 5 weiteren Autor:innen. Beteiligte Einrichtung: Biopharmaceutics Group, Global Clinical Management, Dr. Reddy's Laboratories Ltd., Integrated Product Development Organization (IPDO), Hyderabad, Tel…. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Gastric Inhibitory Polypeptide, Glucagon-Like Peptide 1, Hypoglycemic Agents. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 109 Literaturangaben. Gefördert von: Dr. Reddy's Laboratories Ltd.
Abstract (Originalsprache)
Incretin‐based therapies have become central to type 2 diabetes (T2D) management, offering benefits beyond glycemic control, including weight reduction, cardiovascular protection, and emerging roles in renal and neurological health. This review addresses the question: What are the recent advances in GLP‐1, GIP, and glucagon receptor agonists, and how do formulation strategies overcome biopharmaceutical challenges? We systematically analyzed late‐stage clinical trials and formulation approaches for peptide‐based therapies. The review focuses on therapeutic efficacy, structural and physicochemical properties influencing absorption, distribution, and metabolic stability, and strategies to mitigate degradation pathways such as enzymatic hydrolysis and peptide aggregation. Additionally, innovative delivery systems such as oral peptide formulations and long‐acting injectables demonstrate promise in addressing inherent challenges of peptide drug delivery. By integrating clinical outcomes with mechanistic and formulation insights, this review highlights the evolving landscape of incretin‐based therapies and underscores innovative solutions for peptide stabilization and delivery. These findings provide a forward‐looking perspective for clinicians, researchers, and pharmaceutical scientists engaged in T2D management and drug development.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Biopharmaceutics Group, Global Clinical Management, Dr. Reddy's Laboratories Ltd., Integrated Product Development Organization (IPDO), Hyderabad, Telangana, India.
- Product Selection and Ideation Group (BRaIN), Dr. Reddy's Laboratories Ltd., Integrated Product Development Organization (IPDO), Hyderabad, Telangana, India.
ORCID-Profile: Sivacharan Kollipara
Förderung
- Dr. Reddy's Laboratories Ltd
Zitieren
APA
Khan, M. S., Bhutani, U., Venugopal, H., Saini, A. K., Naidu, V. R., & Kollipara, S. (2026). Emerging Therapies in Metabolic Health: A Comprehensive Review of GLP‐1, GIP, and Glucagon Agonists. Journal of Peptide Science. https://doi.org/10.1002/psc.70083
Vancouver
Khan MS, Bhutani U, Venugopal H, Saini AK, Naidu VR, Kollipara S. Emerging Therapies in Metabolic Health: A Comprehensive Review of GLP‐1, GIP, and Glucagon Agonists. Journal of Peptide Science. 2026. doi:10.1002/psc.70083
BibTeX
@article{Khan2026,
author = {Khan, Mohammed Shareef and Bhutani, Utkarsh and Venugopal, Hariharan and Saini, Anuj Kumar and Naidu, Venkat Ramana and Kollipara, Sivacharan},
title = {Emerging Therapies in Metabolic Health: A Comprehensive Review of GLP‐1, GIP, and Glucagon Agonists},
journal = {Journal of Peptide Science},
year = {2026},
doi = {10.1002/psc.70083}
}
EUVIMED